Drugs / Mycobax
Mycobax
Trials 0
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02207608 Background | Sep 2011 → Aug 2012 | — | University of Rome Tor Vergata | Completed | No outcome recorded |
| Phase 2 | NCT01697306 Comparator | Sep 2006 → Mar 2011 | urinary bladder cancer | A.O.U. Città della Salute e della Scienza | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00003779 Comparator | Nov 1998 → Jun 2001 | urinary bladder cancer | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00568854 Comparator | Apr 2007 → Mar 2008 | diabetes mellitus, tuberculosis | Stanford University | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mycobax | “a single strain of BCG (Mycobax, Sanofi-Aventis)” NCT00568854 ↗ |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02207608 ↗ |
| Known as | BCG Connaught | “Patients were randomized to receive six instillations of BCG Connaught or Tice.” PMID 24674149 ↗ Mar 2014 |
| Known as | Connaught | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003779 ↗ |
| Known as | Immucist | “Group A receive BCG (Immucist® 81 mg, Sanofi-Aventis Group) alone” NCT02207608 ↗ |
| Known as | Immucyst | “six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline” NCT01697306 ↗ |
| Modality | Vaccine | “using the live tuberculosis vaccine, Bacille Calmette-Guerin (BCG)” NCT00568854 ↗ |
| Route | Other | “Both arms receive BCG by catheter” NCT00003779 ↗ |